Leerink Swann says to buy Amarin (Nasdaq: AMRN) into the company's October 116th FDA advisory committee panel meeting, which the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE